Boron Carbide Particle as a Boron Compound for Boron Neutron Capture Therapy

Iwagami Takaki,Ishikawa Yoshie,Koshizaki3 Naoto,Yamamoto Naofumi,Tanaka Hiroki,Masunaga Shin-ichiro,Sakurai Yoshinori,Kato Itsuro,Iwai Soichi,Suzuki Minoru,Yura</p> Yoshiaki,Takaki Iwagami Yoshie Ishikawa

DOI: https://doi.org/10.4172/2155-9619.1000177

2014-01-01

Abstract:In boron neutron capture therapy (BNCT), the intravenous administration of boron-containing

What problem does this paper attempt to address?

Carborane bearing pullulan nanogel-boron oxide nanoparticle hybrid for boron neutron capture therapy

Riku Kawasaki,Hidetoshi Hirano,Keita Yamana,Hinata Isozaki,Shogo Kawamura,Yu Sanada,Kaori Bando,Anri Tabata,Kouhei Yoshikawa,Hideki Azuma,Takushi Takata,Hiroki Tanaka,Yoshinori Sakurai,Minoru Suzuki,Naoki Tarutani,Kiyofumi Katagiri,Shin-Ichi Sawada,Yoshihiro Sasaki,Kazunari Akiyoshi,Takeshi Nagasaki,Atsushi Ikeda

DOI: https://doi.org/10.1016/j.nano.2023.102659

Nanomedicine

Abstract:Boron neutron capture therapy shows is a promising approach to cancer therapy, but the delivery of effective boron agents is challenging. To address the requirements for efficient boron delivery, we used a hybrid nanoparticle comprising a carborane = bearing pullulan nanogel and hydrophobized boron oxide nanoparticle (HBNGs) enabling the preparation of highly concentrated boron agents for efficient delivery. The HBNGs showed better anti-cancer effects on Colon26 cells than a clinically boron agent, L-BPA/fructose complex, by enhancing the accumulation and retention amount of the boron agent within cells in vitro. The accumulation of HBNGs in tumors, due to the enhanced permeation and retention effect, enabled the delivery of boron agents with high tumor selectivity, meeting clinical demands. Intravenous injection of boron neutron capture therapy (BNCT) using HBNGs decreased tumor volume without significant body weight loss, and no regrowth of tumor was observed three months after complete regression. The therapeutic efficacy of HBNGs was better than that of L-BPA/fructose complex. BNCT with HBNGs is a promising approach to cancer therapeutics.
The Development of Boron Analysis and Imaging in Boron Neutron Capture Therapy (BNCT)

Qi Dai,Qiyao Yang,Xiaoyan Bao,Jiejian Chen,Min Han,Qichun Wei

DOI: https://doi.org/10.1021/acs.molpharmaceut.1c00810

2022-01-01

Molecular Pharmaceutics

Abstract:Boron neutron capture therapy (BNCT) is a selective biological targeted nuclide technique for cancer therapy. It has the following attractive features: good targeting, high effectiveness, and causes slight damage to surrounding healthy tissue compared with other traditional methods. It has been considered as one of the promising methods for the treatment of various cancers. Measuring 10B concentrations is vital for BNCT. However, the existing technology and equipment cannot satisfy the real-time and accurate measurement requirements, and more efficient methods are in demand. The development of methods and imaging applied in BNCT to help measure boron concentration is described in this review.
Boron delivery agents for neutron capture therapy of cancer

Rolf F Barth,Peng Mi,Weilian Yang

DOI: https://doi.org/10.1186/s40880-018-0299-7

2018-06-19

Abstract:Boron neutron capture therapy (BNCT) is a binary radiotherapeutic modality based on the nuclear capture and fission reactions that occur when the stable isotope, boron-10, is irradiated with neutrons to produce high energy alpha particles. This review will focus on tumor-targeting boron delivery agents that are an essential component of this binary system. Two low molecular weight boron-containing drugs currently are being used clinically, boronophenylalanine (BPA) and sodium borocaptate (BSH). Although they are far from being ideal, their therapeutic efficacy has been demonstrated in patients with high grade gliomas, recurrent tumors of the head and neck region, and a much smaller number with cutaneous and extra-cutaneous melanomas. Because of their limitations, great effort has been expended over the past 40 years to develop new boron delivery agents that have more favorable biodistribution and uptake for clinical use. These include boron-containing porphyrins, amino acids, polyamines, nucleosides, peptides, monoclonal antibodies, liposomes, nanoparticles of various types, boron cluster compounds and co-polymers. Currently, however, none of these have reached the stage where there is enough convincing data to warrant clinical biodistribution studies. Therefore, at present the best way to further improve the clinical efficacy of BNCT would be to optimize the dosing paradigms and delivery of BPA and BSH, either alone or in combination, with the hope that future research will identify new and better boron delivery agents for clinical use.
Tumor-targeting hyaluronic acid/fluorescent carborane complex for boron neutron capture therapy

Keita Yamana,Riku Kawasaki,Yu Sanada,Anri Tabata,Kaori Bando,Kouhei Yoshikawa,Hideki Azuma,Yoshinori Sakurai,Shin-Ichiro Masunaga,Minoru Suzuki,Kouta Sugikawa,Takeshi Nagasaki,Atsushi Ikeda

DOI: https://doi.org/10.1016/j.bbrc.2021.04.037

2021-06-25

Abstract:In cancer therapeutics, boron neutron capture therapy (BNCT) requires a platform for selective and efficient 10B delivery into tumor tissues for a successful treatment. However, the use of carborane, a promising candidate with high boron content and biostability, has significant limitations in the biomedical field due to its poor water-solubility and tumor-selectivity. To overcome these hurdles, we present in this study a fluorescent nano complex, combining fluorescent carborane and sodium hyaluronate for high boron concentration and tumor-selectivity. Tumor cells actively internalized the complex through binding hyaluronan to CD44, overexpressed on the tumor cell surface. Furthermore, the subcellular distribution of this complex could also be detected due to its fluorescent properties. Moreover, after thermal neutron irradiations, the complex produced excellent cytotoxicity, equal to or greater than that of the clinically-used BPA-fructose. Therefore, this novel complex could be potentially more suitable for BNCT than the boron agent.
Preparation and characterization of Boron carbide nanoparticles for use as a novel agent in T cell-guided boron neutron capture therapy

M W Mortensen,P G Sørensen,O Björkdahl,M R Jensen,H J G Gundersen,T Bjørnholm

DOI: https://doi.org/10.1016/j.apradiso.2005.08.003

Abstract:Boron carbide nanoparticles are proposed as a system for T cell-guided boron neutron capture therapy. Nanoparticles were produced by ball milling in various atmospheres of commercially available boron carbide. The physical and chemical properties of the particles were investigated using transmission electron microscopy, photon correlation spectroscopy, X-ray photoelectron spectroscopy, X-ray diffraction, vibrational spectroscopy, gel electrophoresis and chemical assays and reveal profound changes in surface chemistry and structural characteristics. In vitro thermal neutron irradiation of B16 melanoma cells incubated with sub-100 nm nanoparticles (381.5 microg/g (10)B) induces complete cell death. The nanoparticles alone induce no toxicity.
Boron nanoparticles in chemotherapy and radiotherapy: the synthesis, state-of-the-art, and prospects

S. A. Uspenskii,P. A. Khaptakhanova

DOI: https://doi.org/10.1007/s11172-022-3686-9

2022-12-01

Russian Chemical Bulletin

Abstract:Boron neutron capture therapy (BNCT) is a radiotherapy method for cancer treatment based on the nuclear reaction of the stable 10B isotope with epithermal neutrons that produces high-energy particles affecting the localization site of the isotope. Currently, only two low molecular weight boron-containing compounds (boronophenylalanine and sodium mercaptododecaborate) have been approved for clinical use as targeting agents for BNCT. In spite of positive effects of these substances, certain drawbacks including the low 10B atom content per molecule and low tumor tropism make them of limited use. This review focuses on new-generation targeting agents for BNCT, such as elemental boron, boron carbide, and boron nitride nanoparticles (NPs). Their main advantage is the high content of 10B atoms, e.g., a 3-nm elemental boron NP contains 12000 atoms (cf. 20000 atoms for a 50-nm NP). This allows one to reach the concentration range necessary for successful implementation of BNCT. Information is analyzed and summarized on methods for the synthesis and biological applications of the title targeting agents for BNCT and combined chemotherapy, where NPs can also simultaneously act as drug carriers.

chemistry, multidisciplinary
Boron Neutron Capture Therapy in Clinical Application:Progress and Prospect

Jing Xu,Junjie Wang,Qichun Wei

DOI: https://doi.org/10.1360/tb-2021-0907

2021-01-01

Chinese Science Bulletin (Chinese Version)

Abstract:Boron neutron capture therapy (BNCT) is an emerging radiotherapeutic modality aimed at selectively concentrating boron compounds in tumor cells and then subjecting the tumor cells to neutron beam radiation. Treatment with BNCT is based on the nuclear capture and fission reactions that occur when nonradioactive boron-10 (B-10) is irradiated with neutrons to yield an alpha particle (helium, He-4) and a recoiling lithium-7 (Li-7) nuclei. The He-4 particle has a range of 9 mu m and the Li-7 particle 5 mu m in tissue. In theory, the short range of this reaction limits the damage to malignant cells while sparing adjacent normal cells. The development of BNCT is still constrained by the progress in developing boron delivery agents with a high tumor uptake, low normal tissue uptake, and optimizing the dosing paradigms and quantitative estimation of the B-10 concentrations. It is widely recognized that the second generation boron-containing agents, sodium borocaptate (BSH) and boronophenylalanine (BPA), are less than ideal. New and more effective boron-containing agents are urgently required for clinical use to deliver the requisite amounts of boron to tumor cells. The delivery of boron-containing agent can also be optimized to improve cancer cell uptake and subcellular distribution. Additionally, it is crucial to design high intensity neutron sources and establish hospital-based BNCT. Compared with nuclear reactors. accelerator-based neutron sources are more realistic to be applied in clinical practice. In future, the critical issues regarding novel boron-containing agents, the appropriate delivery strategies, and neutron sources of BNCT for clinical use must be addressed. Two clinical trials with newly diagnosed glioblastoma have been reported. BNCT alone after surgery provided a mean survival time of 17.7 and 19.5 months respectively. The survival outcomes were good as compared to the current standard of care which is post-operation fractionated radiotherapy with concomitant and adjuvant TMZ. Several clinical studies of BNCT in the treatment of recurrent head and neck cancer have been reported. with high response rate and acceptable toxicity. To date, BNCT has been clinically evaluated as an alternative to conventional radiotherapy for the treatment of several tumor types, including newly diagnosed glioblastoma. recurrent glioma, recurrent head and neck tumors, meningioma, malignant melanoma. and liver metastasis. Recently, accelerator-based neutron source has been used in clinical trials for recurrent malignant gliomas and head & neck cancers. Although initial results with BNCT are promising, high-quality prospective clinical trials are still lacking. Well-designed phase II/III clinical research is necessary to define the efficacy and safety of BNCT in various tumor types. Meanwhile, studies comparing the outcomes of BNCT with other standards of care are needed for the further development of BNCT. Based on the previous studies, the BNCT clinical trials in glioblastoma can be initiated with newly diagnosed glioblastoma patients. For other tumor types, late-stage patients with recurrent or metastatic disease after the first-line treatment might be recruited. Last but not the least, in the era of comprehensive treatment for malignant tumor. it is necessary to explore the combined treatment mode of BNCT. For the future research, BNCT may be coupled with a variety of anti-tumor modalities, including traditional photon radiotherapy, immunotherapy, targeted therapy and chemotherapy. It is also possible to explore a variety of drug delivery methods to improve the uptake of boron-containing agents by tumor sites. Multidisciplinary model is needed to jointly promote BNCT to become a routine clinical treatment modality.
Polymer-Stabilized Elemental Boron Nanoparticles for Boron Neutron Capture Therapy: Initial Irradiation Experiments

Alexander Zaboronok,Polina Khaptakhanova,Sergey Uspenskii,Raman Bekarevich,Ludmila Mechetina,Olga Volkova,Bryan J Mathis,Vladimir Kanygin,Eiichi Ishikawa,Anna Kasatova,Dmitrii Kasatov,Ivan Shchudlo,Tatiana Sycheva,Sergey Taskaev,Akira Matsumura

DOI: https://doi.org/10.3390/pharmaceutics14040761

IF: 6.525

2022-03-31

Pharmaceutics

Abstract:Sufficient boron-10 isotope (10B) accumulation by tumor cells is one of the main requirements for successful boron neutron capture therapy (BNCT). The inability of the clinically registered 10B-containing borophenylalanine (BPA) to maintain a high boron tumor concentration during neutron irradiation after a single injection has been partially solved by its continuous infusion; however, its lack of persistence has driven the development of new compounds that overcome the imperfections of BPA. We propose using elemental boron nanoparticles (eBNPs) synthesized by cascade ultrasonic dispersion and destruction of elemental boron microparticles and stabilized with hydroxyethylcellulose (HEC) as a core component of a novel boron drug for BNCT. These HEC particles are stable in aqueous media and show no apparent influence on U251, U87, and T98G human glioma cell proliferation without neutron beam irradiation. In BNCT experiments, cells incubated with eBNPs or BPA at an equivalent concentration of 40 µg 10B/mL for 24 h or control cells without boron were irradiated at an accelerator-based neutron source with a total fluence of thermal and epithermal neutrons of 2.685, 5.370, or 8.055 × 1012/cm2. The eBNPs significantly reduced colony-forming capacity in all studied cells during BNCT compared to BPA, verified by cell-survival curves fit to the linear-quadratic model and calculated radiobiological parameters, though the effect of both compounds differed depending on the cell line. The results of our study warrant further tumor targeting-oriented modifications of synthesized nanoparticles and subsequent in vivo BNCT experiments.
Laser-Synthesized Elemental Boron Nanoparticles for Efficient Boron Neutron Capture Therapy

Irina N Zavestovskaya,Anna I Kasatova,Dmitry A Kasatov,Julia S Babkova,Ivan V Zelepukin,Ksenya S Kuzmina,Gleb V Tikhonowski,Andrei I Pastukhov,Kuder O Aiyyzhy,Ekaterina V Barmina,Anton A Popov,Ivan A Razumov,Evgenii L Zavjalov,Maria S Grigoryeva,Sergey M Klimentov,Vladimir A Ryabov,Sergey M Deyev,Sergey Yu Taskaev,Andrei V Kabashin

DOI: https://doi.org/10.3390/ijms242317088

2023-12-04

Abstract:Boron neutron capture therapy (BNCT) is one of the most appealing radiotherapy modalities, whose localization can be further improved by the employment of boron-containing nanoformulations, but the fabrication of biologically friendly, water-dispersible nanoparticles (NPs) with high boron content and favorable physicochemical characteristics still presents a great challenge. Here, we explore the use of elemental boron (B) NPs (BNPs) fabricated using the methods of pulsed laser ablation in liquids as sensitizers of BNCT. Depending on the conditions of laser-ablative synthesis, the used NPs were amorphous (a-BNPs) or partially crystallized (pc-BNPs) with a mean size of 20 nm or 50 nm, respectively. Both types of BNPs were functionalized with polyethylene glycol polymer to improve colloidal stability and biocompatibility. The NPs did not initiate any toxicity effects up to concentrations of 500 µg/mL, based on the results of MTT and clonogenic assay tests. The cells with BNPs incubated at a 10B concentration of 40 µg/mL were then irradiated with a thermal neutron beam for 30 min. We found that the presence of BNPs led to a radical enhancement in cancer cell death, namely a drop in colony forming capacity of SW-620 cells down to 12.6% and 1.6% for a-BNPs and pc-BNPs, respectively, while the relevant colony-forming capacity for U87 cells dropped down to 17%. The effect of cell irradiation by neutron beam uniquely was negligible under these conditions. Finally, to estimate the dose and regimes of irradiation for future BNCT in vivo tests, we studied the biodistribution of boron under intratumoral administration of BNPs in immunodeficient SCID mice and recorded excellent retention of boron in tumors. The obtained data unambiguously evidenced the effect of a neutron therapy enhancement, which can be attributed to efficient BNP-mediated generation of α-particles.
Boron Vehiculating Nanosystems for Neutron Capture Therapy in Cancer Treatment

Giorgia Ailuno,Alice Balboni,Gabriele Caviglioli,Francesco Lai,Federica Barbieri,Irene Dellacasagrande,Tullio Florio,Sara Baldassari

DOI: https://doi.org/10.3390/cells11244029

IF: 6

2022-12-14

Cells

Abstract:Boron neutron capture therapy is a low-invasive cancer therapy based on the neutron fission process that occurs upon thermal neutron irradiation of 10B-containing compounds; this process causes the release of alpha particles that selectively damage cancer cells. Although several clinical studies involving mercaptoundecahydro-closo-dodecaborate and the boronophenylalanine–fructose complex are currently ongoing, the success of this promising anticancer therapy is hampered by the lack of appropriate drug delivery systems to selectively carry therapeutic concentrations of boron atoms to cancer tissues, allowing prolonged boron retention therein and avoiding the damage of healthy tissues. To achieve these goals, numerous research groups have explored the possibility to formulate nanoparticulate systems for boron delivery. In this review. we report the newest developments on boron vehiculating drug delivery systems based on nanoparticles, distinguished on the basis of the type of carrier used, with a specific focus on the formulation aspects.

cell biology
HER-2-Targeted Boron Neutron Capture Therapy with Carborane-integrated Immunoliposomes Prepared via an Exchanging Reaction

Riku Kawasaki,Ayano Oshige,Keita Yamana,Hidetoshi Hirano,Kotaro Nishimura,Yamato Miura,Ryuji Yorioka,Yu Sanada,Kaori Bando,Anri Tabata,Kazuma Yasuhara,Yusuke Miyazaki,Wataru Shinoda,Tomoki Nishimura,Hideki Azuma,Takushi Takata,Yoshinori Sakurai,Hiroki Tanaka,Minoru Suzuki,Takeshi Nagasaki,Atsushi Ikeda

DOI: https://doi.org/10.1002/chem.202302486

2023-12-22

Chemistry

Abstract:Boron neutron capture therapy (BNCT) is a promising modality for cancer treatment because of its minimal invasiveness. To maximize the therapeutic benefits of BNCT, the development of efficient platforms for the delivery of boron agents is indispensable. Here, carborane-integrated immunoliposomes were prepared via an exchanging reaction to achieve HER-2-targeted BNCT. The conjugation of an anti-HER-2 antibody to carborane-integrated liposomes successfully endowed these liposomes with targeting properties toward HER-2-overexpressing human ovarian cancer cells (SK-OV3); the resulting BNCT activity toward SK-OV3 cells obtained using the current immunoliposomal system was 14-fold that of the l-BPA/fructose complex, which is a clinically available boron agent. Moreover, the growth of spheroids treated with this system followed by thermal neutron irradiation was significantly suppressed compared with treatment with the l-BPA/fructose complex.
Self-assembling A6K peptide nanotubes as a mercaptoundecahydrododecaborate (BSH) delivery system for boron neutron capture therapy (BNCT)

Hiroyuki Michiue,Mizuki Kitamatsu,Asami Fukunaga,Nobushige Tsuboi,Atsushi Fujimura,Hiroaki Matsushita,Kazuyo Igawa,Tomonari Kasai,Natsuko Kondo,Hideki Matsui,Shuichi Furuya

DOI: https://doi.org/10.1016/j.jconrel.2020.11.001

2021-02-10

Abstract:Boron neutron capture therapy (BNCT) is a tumor selective therapy, the effectiveness of which depends on sufficient 10B delivery to and accumulation in tumors. In this study, we used self-assembling A6K peptide nanotubes as boron carriers and prepared new boron agents by simple mixing of A6K and BSH. BSH has been used to treat malignant glioma patients in clinical trials and its drug safety and availability have been confirmed; however, its contribution to BNCT efficacy is low. A6K nanotube delivery improved two major limitations of BSH, including absence of intracellular transduction and non-specific drug delivery to tumor tissue. Varying the A6K peptide and BSH mixture ratio produced materials with different morphologies-determined by electron microscopy-and intracellular transduction efficiencies. We investigated the A6K/BSH 1:10 mixture ratio and found high intracellular boron uptake with no toxicity. Microscopy observation showed intracellular localization of A6K/BSH in the perinuclear region and endosome in human glioma cells. The intracellular boron concentration using A6K/BSH was almost 10 times higher than that of BSH. The systematic administration of A6K/BSH via mouse tail vein showed tumor specific accumulation in a mouse brain tumor model with immunohistochemistry and pharmacokinetic study. Neutron irradiation of glioma cells treated with A6K/BSH showed the inhibition of cell proliferation in a colony formation assay. Boron delivery using A6K peptide provides a unique and simple strategy for next generation BNCT drugs.
Boron agent delivery platforms based on natural products for boron neutron capture therapy

Riku Kawasaki,Yamato Miura,Nanami Kono,Seiya Fujita,Keita Yamana,Atsushi Ikeda

DOI: https://doi.org/10.1002/cmdc.202400323

IF: 3.54

2024-06-05

ChemMedChem

Abstract:Boron neutron capture therapy (BNCT) is one of the most promising modalities for cancer treatment due to its minimal invasiveness. Although two types of boron agents are clinically used, several issues persist in their delivery, including poor water solubility, instability in aqueous media, selectivity toward cancer cells, accumulation in cancer cells, retention time in tumor tissue, and efficiency in achieving the boron neutron capture reaction. Addressing these challenges, numerous groups have explored various boron agents to enhance the therapeutic benefits of BNCT. This review summarizes delivery platforms based on natural products for BNCT.

pharmacology & pharmacy,chemistry, medicinal
Application of Nitroimidazole-Carbobane-Modified Phenylalanine Derivatives as Dual-Target Boron Carriers in Boron Neutron Capture Therapy

Ruixi Li,Juanjuan Zhang,Jingxuan Guo,Yue Xu,Kunyuan Duan,Jinrong Zheng,Hao Wan,Zhenwei Yuan,Haiyan Chen

DOI: https://doi.org/10.1021/acs.molpharmaceut.9b00898

2020-01-06

Abstract:Boron neutron capture therapy (BNCT) has received extensive attention as noninvasive cell-level oncotherapy for treating solid cancer tumors. However, boron-containing drugs such as l-boronophenylalanine (BPA) and sodium borocaptate have low boron content and/or poor tumor-targeting ability, limiting their application. In this study, we designed and synthesized a series of nontoxic, dual-target boron carriers (B139, B142, and B151) with the ability to accumulate specifically in tumor cells. We found that the B139 uptake into hypoxic tumor regions was high, with a 70-fold boron content compared to BPA. In addition, in vivo observation showed that B139 can be trapped in tumor cells for a prolonged period and maintains an effective therapeutic concentration, with a peak boron concentration of 50.7 μg/g and a high tumor: blood boron ratio of >3, achieving ideal BNCT conditions. Cytotoxicity evaluation in mice further proved that B139 is safe and reliable. Therefore, B139 has great potential for BNCT application as a dual-target, safe, and efficient boron carrier.
Evaluation of a Novel Boron-Containing α-D-Mannopyranoside for BNCT

Takao Tsurubuchi,Makoto Shirakawa,Wataru Kurosawa,Kayo Matsumoto,Risa Ubagai,Hiroshi Umishio,Yasuyo Suga,Junko Yamazaki,Akihiro Arakawa,Yutaka Maruyama,Takuya Seki,Yusuke Shibui,Fumiyo Yoshida,Alexander Zaboronok,Minoru Suzuki,Yoshinori Sakurai,Hiroki Tanaka,Kei Nakai,Eiichi Ishikawa,Akira Matsumura

DOI: https://doi.org/10.3390/cells9051277

IF: 6

2020-05-21

Cells

Abstract:Boron neutron capture therapy (BNCT) is a unique anticancer technology that has demonstrated its efficacy in numerous phase I/II clinical trials with boronophenylalanine (BPA) and sodium borocaptate (BSH) used as 10B delivery agents. However, continuous drug administration at high concentrations is needed to maintain sufficient 10B concentration within tumors. To address the issue of 10B accumulation and retention in tumor tissue, we developed MMT1242, a novel boron-containing α-d-mannopyranoside. We evaluated the uptake, intracellular distribution, and retention of MMT1242 in cultured cells and analyzed biodistribution, tumor-to-normal tissue ratio and toxicity in vivo. Fluorescence imaging using nitrobenzoxadiazole (NBD)-labeled MMT1242 and inductively coupled mass spectrometry (ICP-MS) were performed. The effectiveness of BNCT using MMT1242 was assessed in animal irradiation studies at the Kyoto University Research Reactor. MMT1242 showed a high uptake and broad intracellular distribution in vitro, longer tumor retention compared to BSH and BPA, and adequate tumor-to-normal tissue accumulation ratio and low toxicity in vivo. A neutron irradiation study with MMT1242 in a subcutaneous murine tumor model revealed a significant tumor inhibiting effect if injected 24 h before irradiation. We therefore report that 10B-MMT1242 is a candidate for further clinical BNCT studies.
HER-2-targeted boron neutron capture therapy using an antibody-conjugated boron nitride nanotube/β-1,3-glucan complex

Keita Yamana,Riku Kawasaki,Kousuke Kondo,Hidetoshi Hirano,Shogo Kawamura,Yu Sanada,Kaori Bando,Anri Tabata,Hideki Azuma,Takushi Takata,Yoshinori Sakurai,Hiroki Tanaka,Tomoki Kodama,Seiji Kawamoto,Takeshi Nagasaki,Atsushi Ikeda

DOI: https://doi.org/10.1039/d3na00028a

2023-06-01

Abstract:The development of boron agents with integrated functionality, including biocompatibility, high boron content, and cancer cell targeting, is desired to exploit the therapeutic efficacy of boron neutron capture therapy (BNCT). Here, we report the therapeutic efficacy of BNCT using a HER-2-targeted antibody-conjugated boron nitride nanotube/β-1,3-glucan complex. The anticancer effect of BNCT using our system was 30-fold that of the clinically available boron agent l-BPA/fructose complex.
New Boron Delivery Agents

Annette G Beck-Sickinger,Daniel P Becker,Oksana Chepurna,Bhaskar Das,Sebastian Flieger,Evamarie Hey-Hawkins,Narayan Hosmane,Satish S Jalisatgi,Hiroyuki Nakamura,Rameshwar Patil,Maria da Graça H Vicente,Clara Viñas

DOI: https://doi.org/10.1089/cbr.2022.0060

Abstract:This proceeding article compiles current research on the development of boron delivery drugs for boron neutron capture therapy that was presented and discussed at the National Cancer Institute (NCI) Workshop on Neutron Capture Therapy that took place on April 20-22, 2022. The most used boron sources are icosahedral boron clusters attached to peptides, proteins (such as albumin), porphyrin derivatives, dendrimers, polymers, and nanoparticles, or encapsulated into liposomes. These boron clusters and/or carriers can be labeled with contrast agents allowing for the use of imaging techniques, such as PET, SPECT, and fluorescence, that enable quantification of tumor-localized boron and their use as theranostic agents.
Synthesis and in vitro evaluation of boronated uridine and glucose derivatives for boron neutron capture therapy

W Tjarks,A K Anisuzzaman,L Liu,A H Soloway,R F Barth,D J Perkins,D M Adams

DOI: https://doi.org/10.1021/jm00087a019

1992-05-01

Abstract:The following boron-containing nucleoside and glucose derivatives have been synthesized as potential boron delivery agents for boron neutron capture therapy (BNCT): 2'-O-(o-carboran-1-ylmethyl)uridine (4a), 3'-O-(o-carboran-1-ylmethyl)uridine (4b), sodium 7-(uridin-2'-ylmethyl)dodecahydro-7,8-dicarba-++ +nido-undecaborate (5), 5'-O-(o-carboran-1-ylmethyl)uridine (9), and 3'-O-(o-carboran-1-ylmethyl)-D-glucose (13). In vitro cellular uptake studies were performed with F98 rat glioma cells. Following 16 h incubation, cellular boron concentrations were determined by direct current plasma atomic emission spectroscopy (DCP-AES). Boron concentrations ranged from 65 to 103 micrograms/g of cells for the neutral closo structures compared with 1.5 micrograms/g of cells for the charged nido species. Cellular uptake of sodium mercaptoundecahydro-closo-dodecaborate (BSH), the compound currently being used in Japan for the treatment of malignant brain tumors by BNCT, was 2 micrograms/g of cells.
Organosilica nanoparticles containing sodium borocaptate (BSH) provide new prospects for boron neutron capture therapy (BNCT): efficient cellular uptake and enhanced BNCT efficacy

Mathilde Laird,Kotaro Matsumoto,Yuya Higashi,Aoi Komatsu,Art Raitano,Kendall Morrison,Minoru Suzuki,Fuyuhiko Tamanoi

DOI: https://doi.org/10.1039/d2na00839d

2023-04-03

Abstract:Boron neutron capture therapy (BNCT), a method based on the fission of boron-10 upon neutron irradiation, has emerged as an attractive option for radiation therapy. To date, the main drugs used in BNCT are 4-boronophenylalanine (BPA) and sodium borocaptate (BSH). While BPA has been extensively tested in clinical trials, the use of BSH has been limited, mainly due to its poor cellular uptake. Here, we describe a novel type of mesoporous silica-based nanoparticle containing BSH covalently attached to a nanocarrier. Synthesis and characterization of these nanoparticles (BSH-BPMO) are presented. The synthetic strategy involves a click thiol-ene reaction with the boron cluster, providing hydrolytically stable linkage with the BSH in four steps. The BSH-BPMO nanoparticles were efficiently taken up into cancer cells and accumulated in the perinuclear region. Inductively coupled plasma (ICP) measurements of boron uptake in cells highlight the important role of the nanocarrier in the enhancement of boron internalization. BSH-BPMO nanoparticles were also taken up and distributed throughout tumour spheroids. BNCT efficacy was examined by the neutron exposure of the tumour spheroids. BSH-BPMO loaded spheroids were completely destroyed upon neutron irradiation. In contrast, neutron irradiation of tumour spheroids loaded with BSH or BPA resulted in significantly less spheroid shrinkage. The significant difference in BNCT efficacy of the BSH-BPMO was correlated with the improved boron uptake via the nanocarrier. Overall, these results demonstrate the critical role of the nanocarrier in BSH internalization and the enhanced BNCT efficacy of the BSH-BPMO compared with BSH and BPA, two drugs used in BNCT clinical trials.
Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy

Micah John Luderer,Pilar de la Puente,Abdel Kareem Azab

DOI: https://doi.org/10.1007/s11095-015-1718-y

Abstract:Boron neutron capture therapy (BNCT) is a promising cancer therapy modality that utilizes the nuclear capture reaction of epithermal neutrons by boron-10 resulting in a localized nuclear fission reaction and subsequent cell death. Since cellular destruction is limited to approximately the diameter of a single cell, primarily only cells in the neutron field with significant boron accumulation will be damaged. However, the emergence of BNCT as a prominent therapy has in large part been hindered by a paucity of tumor selective boron containing agents. While L-boronophenylalanine and sodium borocaptate are the most commonly investigated clinical agents, new agents are desperately needed due to their suboptimal tumor selectivity. This review will highlight the various strategies to improve tumor boron delivery including: nucleoside and carbohydrate analogs, unnatural amino acids, porphyrins, antibody-dendrimer conjugates, cationic polymers, cell-membrane penetrating peptides, liposomes and nanoparticles.

Boron Carbide Particle as a Boron Compound for Boron Neutron Capture Therapy

Carborane bearing pullulan nanogel-boron oxide nanoparticle hybrid for boron neutron capture therapy

The Development of Boron Analysis and Imaging in Boron Neutron Capture Therapy (BNCT)

Boron delivery agents for neutron capture therapy of cancer

Tumor-targeting hyaluronic acid/fluorescent carborane complex for boron neutron capture therapy

Preparation and characterization of Boron carbide nanoparticles for use as a novel agent in T cell-guided boron neutron capture therapy

Boron nanoparticles in chemotherapy and radiotherapy: the synthesis, state-of-the-art, and prospects

Boron Neutron Capture Therapy in Clinical Application:Progress and Prospect

Polymer-Stabilized Elemental Boron Nanoparticles for Boron Neutron Capture Therapy: Initial Irradiation Experiments

Laser-Synthesized Elemental Boron Nanoparticles for Efficient Boron Neutron Capture Therapy

Boron Vehiculating Nanosystems for Neutron Capture Therapy in Cancer Treatment

HER-2-Targeted Boron Neutron Capture Therapy with Carborane-integrated Immunoliposomes Prepared via an Exchanging Reaction

Self-assembling A6K peptide nanotubes as a mercaptoundecahydrododecaborate (BSH) delivery system for boron neutron capture therapy (BNCT)

Boron agent delivery platforms based on natural products for boron neutron capture therapy

Application of Nitroimidazole-Carbobane-Modified Phenylalanine Derivatives as Dual-Target Boron Carriers in Boron Neutron Capture Therapy

Evaluation of a Novel Boron-Containing α-D-Mannopyranoside for BNCT

HER-2-targeted boron neutron capture therapy using an antibody-conjugated boron nitride nanotube/β-1,3-glucan complex

New Boron Delivery Agents

Synthesis and in vitro evaluation of boronated uridine and glucose derivatives for boron neutron capture therapy

Organosilica nanoparticles containing sodium borocaptate (BSH) provide new prospects for boron neutron capture therapy (BNCT): efficient cellular uptake and enhanced BNCT efficacy

Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy